# US 2025/0051451 A1 · Anti-b7-h3 monoclonal antibody and use thereof in cell therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0051451 A1
- Document ID: US20250051451A1
- Status: Published application
- Kind: A1
- Application number: 18/815,779
- Filed: 2024-08-26
- Published: 2025-02-13
- Earliest claimed: 2018-09-26
- Assignees: Fuzhou Tcelltech Biotechnology Co., Ltd.; Tcelltech Inc.
- Applicants: Fuzhou Tcelltech Biotechnology Co., Ltd.; Tcelltech Inc.
- Inventors: Gangxiong HUANG; Liqun LUO
- Web page: https://patentgrep.com/patent/US20250051451A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/50: Colon
- A61K 2239/55: Lung
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/24: containing a MBP (maltose binding protein)-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K 2319/92: containing an intein ("protein splicing")domain
- C12N 2510/00: Genetically modified cells
- G01N 2333/70532: B7 molecules, e.g. CD80, CD86
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides an anti-B7-H3 monoclonal antibody and use thereof in cell therapy. Specifically, the present invention provides an scFv, an antibody, and a specific CAR-T cell specifically targeting B7-H3. The present invention further provides an engineered immune cell capable of co-expressing a CAR targeting B7-H3 and a chimeric molecule or a secreted protein of PD-L1, the engineered immune cell having good tumor killing effects.

## Claims

### Claim 1

An antibody binding B7-H3, wherein the antibody has:
(1) a heavy chain variable region; and
(2) a light chain variable region;
the heavy chain variable region comprises the following three complementary determining regions (CDRs):
CDR 1 as shown in SEQ ID NO: 3,
CDR2 as shown in SEQ ID NO: 6, and
CDR3 as shown in SEQ ID NO: 9;
the light chain variable region comprises the following three complementary determining regions (CDRs):
CDR1′ as shown in SEQ ID NO: 12,
CDR2′ as shown in SEQ ID NO: 15, and
CDR3′ as shown in SEQ ID NO: 18.

### Claim 2 (depends on 1)

A recombinant protein, wherein the recombinant protein has:
(i) the antibody of claim 1; and
(ii) an optional tag sequence assisting expression and/or purification.

### Claim 3

A CAR construct, wherein an antigen binding region of the CAR construct is an scFv that specifically binds to B7-H3, and the scFv has a heavy chain variable region and a light chain variable region;
the heavy chain variable region comprises the following three complementary determining regions (CDRs):
CDR1 as shown in SEQ ID NO: 3,
CDR2 as shown in SEQ ID NO: 6, and
CDR3 as shown in SEQ ID NO: 9;
the light chain variable region comprises the following three complementary determining regions (CDRs):
CDR1′ as shown in SEQ ID NO: 12,
CDR2′ as shown in SEQ ID NO: 15, and
CDR3′ as shown in SEQ ID NO: 18.

### Claim 4 (depends on 3)

An engineered immune cell, wherein the immune cell comprises:
(a) a first expression cassette for expressing the exogenous CAR construct of claim 3; and
(b) an optional second expression cassette for expressing a fusion protein containing PD1-CD28 or PD1-IL7R.

### Claim 5 (depends on 1)

An antibody-drug conjugate, wherein the antibody-drug conjugate comprises:
(a) an antibody portion, selected from the antibody of claim 1; and
(b) a conjugating portion conjugated to the antibody portion, the conjugating portion is selected from the group consisting of detectable markers, drugs, toxins, cytokines, radionuclides, enzymes, and combinations thereof.

### Claim 6 (depends on 1)

A method for preventing and/or treating a cancer or tumor comprising administering an effective amount of the antibody of claim 1, a recombinant protein comprising the antibody, a CAR construct, an immune cell expressing the CAR construct, an antibody drug conjugate comprising the antibody, or a combination thereof to a subject in need thereof, wherein the CAR construct comprises an scFv having a heavy chain variable region and a light chain variable region,
wherein the heavy chain variable region comprises the following three complementary determining regions (CDRs):
CDR1 as shown in SEQ ID NO: 3,
CDR2 as shown in SEQ ID NO: 6, and
CDR3 as shown in SEQ ID NO: 9; and
wherein the light chain variable region comprises the following three complementary determining regions (CDRs):
CDR1′ as shown in SEQ ID NO: 12,
CDR2′ as shown in SEQ ID NO: 15, and
CDR3′ as shown in SEQ ID NO: 18.

### Claim 7 (depends on 1)

A pharmaceutical composition, wherein the pharmaceutical composition comprises:
the antibody of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 8 (depends on 1)

A polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:
(1) the antibody of claim 1;
(2) the recombinant protein comprising the antibody; and
(3) the CAR construct comprising an scFv having a heavy chain variable region and a light chain variable region,
wherein the heavy chain variable region comprises the following three complementary determining regions (CDRs):
CDR1 as shown in SEQ ID NO: 3,
CDR2 as shown in SEQ ID NO: 6, and
CDR3 as shown in SEQ ID NO: 9; and
wherein the light chain variable region comprises the following three complementary determining regions (CDRs):
CDR1′ as shown in SEQ ID NO: 12,
CDR2′ as shown in SEQ ID NO: 15, and
CDR3′ as shown in SEQ ID NO: 18.

### Claim 9 (depends on 8)

A vector, wherein the vector comprises the polynucleotide of claim 8.

### Claim 10 (depends on 9)

A genetically engineered host cell, wherein the host cell comprises the vector of claim 9.

### Claim 11 (depends on 3)

A method for preparing an engineered immune cell, comprising the following steps:
(A) providing an immune cell to be modified; and
(B) introducing a first expression cassette and/or an optional second expression cassette into the immune cell to be modified, wherein the first expression cassette expresses the CAR construct of claim 3, and the second expression cassette expresses a fusion protein containing PD1-CD28 or PD1-IL7R, thereby obtaining the engineered immune cell.

### Claim 12 (depends on 1)

A method for testing a B7-H3 protein in a sample in vitro, comprising the following steps:
(1) contacting the sample with the antibody of claim 1 in vitro; and
(2) testing whether an antigen-antibody complex is formed, wherein the formation of the complex indicates the presence of the B7-H3 protein in the sample.

### Claim 13 (depends on 1)

A test plate, wherein the test plate comprises: a substrate (support plate) and a test strip, the test strip containing the antibody of claim 1.

### Claim 14 (depends on 3)

A kit for preparing the engineered immune cell, wherein the kit comprises:
(a) a first container, and a first nucleotide molecule in the first container, the first nucleotide molecule containing a first expression cassette for expressing the CAR construct of claim 3; and
optionally (b) a second container, and a second nucleotide molecule in the second container, the second nucleotide molecule containing a second expression cassette for expressing the fusion protein.

### Claim 15 (depends on 1)

A diagnostic kit, comprising:
(1) a first container containing the antibody of claim 1; and/or
(2) a second container containing a secondary antibody against the antibody of claim 1.
